BeiGene | Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Chemoradiotherapy in Participant With ESCC

⟵ Back to Search Results

Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Chemoradiotherapy in Participant With ESCC

Beigene Study ID

BGB-A317-311

ClinicalTrials.gov ID

NCT03957590

China Drug Trials ID

CTR20190198

Sex: All

Age: 18 Years / 75 Years

No Study Documents

Sex: All

Age: 18 Years / 75 Years

No Study Documents